Pharma BD Deal Intelligence
Actavis's $25B, all-cash-and-stock buy of Forest Laboratories landed as a clean bolt-on rather than a bet-the-company gamble: Forest's branded portfolio, anchored by Namenda, slotted straight into Actavis's roll-up strategy and closed on schedule just four months after announcement.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Actavis to acquire Forest Laboratories for approximately $25 billion, or $89.48 per Forest share consisting of $26.04 in cash and 0.3306 Actavis shares for…
Actavis acquired Forest Laboratories for $20.7B.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Actavis acquired Forest Laboratories for approximately $25B ($28.38 per share in cash and stock). Deal announced February 2014, closed June 2014. The acquisition gave Actavis Forest's branded pharmaceutical portfolio including Namenda (memantine) and pipeline assets.
500K US cases/yr · $3.5B US Alzheimer's Rx Market (2014) · $1.5B Namenda Revenue (2013)
Forest Laboratories' crown jewel was Namenda (memantine), the only approved NMDA receptor antagonist for moderate-to-severe Alzheimer's. With $1.5B in annual sales, Namenda was facing imminent generic competition. Forest launched Namenda XR (extended-release) and attempted a controversial 'forced switch' from IR to XR to extend exclusivity, which was blocked by courts.
The AD symptomatic treatment market was mature and genericizing: Aricept (donepezil) had already gone generic. Namenda XR extended the franchise briefly but generics arrived in 2015. Beyond Namenda, Forest brought a diversified portfolio including Bystolic (nebivolol), Daliresp (roflumilast), and Viibryd (vilazodone). Actavis used the Forest acquisition as a stepping stone to the $70.5B Allergan deal later in 2014.
Actavis enters merger agreement to acquire Forest Laboratories for ~$25B in cash and equity, targeting Namenda (Alzheimer), Linzess (GI), and branded specialty pipeline.
Forest Laboratories stockholders vote to approve the merger at a special meeting, clearing the governance hurdle for the combination.
FTC approves the acquisition on condition that Actavis and Forest divest rights to certain overlapping generic drugs to preserve competition.
Actavis completes acquisition of Forest Laboratories at a final valuation of approximately $28B (up from $25B at announcement), gaining Namenda and Linzess.
Actavis pushes Namenda franchise conversion to extended-release formulation (Namenda XR) at ~49% conversion rate, defending against imminent generic Namenda IR entry.
Actavis closes its $66B acquisition of Allergan and renames the combined company Allergan plc, making Forest Labs one layer in a serial M&A strategy.
Forest Labs gave Actavis a branded specialty portfolio (Namenda, Linzess, Daliresp) that improved revenue mix and justified the subsequent Allergan mega-deal. Linzess became a multi-billion-dollar GI franchise. The Namenda-to-XR conversion was legally challenged but Forest as an acquisition created strong net value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Actavis plc / Forest Laboratories, Inc. (this deal) | 2014 | $25.0B | 75 |
| Actavis plc / Warner Chilcott plc | 2013 | $8.5B | 63 |
| Actavis plc / Allergan plc | 2014 | $70.5B | 61 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2014 deals · Actavis plc deals · Neurology deals